Search

Displaying results 3881 - 3890 of 10000 in total
  1. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    (completed for type 1 diabetes), and NCT05581043 (completed for type 2 diabetes). … Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236

    Synonyms: 3-HYDROXYBUTYRIC ACID, 3-HYDROXY-BUTANOIC ACID
  2. Drug

    105AD7

    go.drugbank.com/drugs/DB05113
    Investigational

    105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in … metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.

  3. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). … The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.

  4. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

  5. Drug

    EHC18

    go.drugbank.com/drugs/DB05114
    Experimental

    EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.

  6. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

  7. Drug

    Votucalis

    go.drugbank.com/drugs/DB05032
    Investigational

    rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.

  8. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    This drug is developed by Ceregene and currently under phase I of clinical trial. … CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    3-Methylfentanyl

    go.drugbank.com/drugs/DB01571
    ExperimentalIllicit

    3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000 … times more potent than morphine in certain cases. 3-Methylfentanyl was initially discovered in 1974 and widespread illegal use of this drug has occurred since this time.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 3-MF